Reviewer’s report

Title: The clinical response to vemurafenib in a patient with a rare BRAFV600DK601del mutation-positive melanoma.

Version: 2
Date: 29 June 2014

Reviewer: Jochen Gaedcke

Reviewer’s report:

The report by Trudel et al. is well and clearly written, and comes to the important information that patients with the retrieved, specific mutation are well treated by vemurafenib.

In this context the authors describe the difficulties in detecting rare mutations/deletions and the potential misleading (not in this case). Therefore, the authors should comment whether the retrieved data in the past from V600E mutations have the potential of being misdiagnosed.

Second, the authors state that rare mutations are not known to be targeted by vemurafenib. They should comment if their analyzes are a potential approach to answer the question before treatment is started. Or, alternately, which approach they would suggest.

Level of interest: An article of outstanding merit and interest in its field

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

I declare that I have no competing interests